AstraZeneca completes $2.4 billion acquisition of Fusion Pharma
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs
Health
Pharma